A Decision Model to Compare Health Care Costs of Olanzapine and Risperidone Treatment for Schizophrenia in Germany

Second-generation atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, ziprasidone, amisulpride and ariprazole offer the potential to reduce the significant health care resource demands in the treatment of schizophrenia through improved levels of initial clinical response...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European journal of health economics 2006-09, Vol.7 (3), p.165-172
Hauptverfasser:	Beard, Stephen M., Maciver, Fiona, Clouth, Johannes, Rüther, Eckart
Format:	Artikel
Sprache:	eng
Schlagworte:	Antipsychotic agents Antipsychotic Agents - economics Antipsychotic Agents - therapeutic use Antipsychotics Benzodiazepines - economics Benzodiazepines - therapeutic use Clinical trials Comparative studies Cost control Cost savings Decision Support Techniques Drug design Drug therapy Economic models Germany Health care Health Care Costs Health care expenditures Health economics Hospitalization - economics Humans Maintenance costs Mental disorders Original Papers Psychotropic drugs Quality-Adjusted Life Years Recurrence Relapse Risperidone - economics Risperidone - therapeutic use Schizophrenia Schizophrenia - drug therapy Schizophrenia - economics Schizophrenia - prevention & control Suicide Suicide - prevention & control Symptoms Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!